High glucose-induced impairment in insulin secretion is associated with reduction in islet glucokinase in a mouse model of susceptibility to islet dysfunction

Suwattanee Kooptiwut, Melkam Kebede, Sakeneh Zraika, Sherley Visinoni, Kathryn Aston-Mourney, Jenny Favaloro, Chris Tikellis¹, Merlin C Thomas¹, Josephine M Forbes¹, Mark E Cooper¹, Marjorie Dunlop, Joseph Proietto and Sofianos Andrikopoulos

University of Melbourne, Department of Medicine (AH/NH), Heidelberg Repatriation Hospital, 300 Waterdale Road, Heidelberg Heights, Victoria 3081, Australia

¹Baker Heart Research Institute, Melbourne, Victoria 3004, Australia

(Requests for offprints should be addressed to S Andrikopoulos, Email: sof@unimelb.edu.au)

Abstract

Type 2 diabetes is characterized by islet dysfunction resulting in hyperglycemia, which can then lead to further deterioration in islet function. A possible mechanism for hyperglycemia-induced islet dysfunction is the accumulation of advanced glycation end products (AGE). The DBA/2 mouse develops pancreatic islet dysfunction when exposed to a high glucose environment and/or obesity-induced insulin resistance. To determine the biochemical cause of dysfunction, DBA/2 and C57BL/6 control islets were incubated in 11.1 mM or 40 mM glucose in the absence or presence of the AGE inhibitor aminoguanidine (AG) for 10 days. Basal (2.8 mM glucose) insulin release was increased in both DBA/2 and C57BL/6 islets incubated with 40 mM vs 11.1 mM glucose for 10 days. Chronic exposure to hyperglycemia decreased glucose (20 mM)-stimulated insulin secretion in DBA/2 but not in C57BL/6 islets. AG significantly increased fold-induced insulin release in high glucose cultured DBA/2 mouse islets, but did not affect C57BL/6 islet function. DBA/2 islet glucokinase was significantly reduced following 40 mM glucose culture, compared with 11.1 mM glucose cultured DBA/2 islets and 40 mM glucose cultured C57BL/6 islets. Incubation of islets with AG resulted in a normalization of DBA/2 islet glucokinase levels. In conclusion, chronic high glucose-induced increases in AGE can result in islet dysfunction and this is associated with reduced glucokinase levels in a mouse model with susceptibility to islet failure.

Journal of Molecular Endocrinology (2005) 35, 39–48

Introduction

Reduced glucose-mediated insulin release is a characteristic feature of type 2 diabetes resulting in hyperglycemia (Porte 1991). Furthermore, both in vivo (Leahy et al. 1987, Bedoya & Jeannenaud 1991) and in vitro (Davalli et al. 1991, Robertson et al. 1992) studies have shown that hyperglycemia itself can activate pathways which diminish glucose-mediated insulin release. Thus, this has the possibility of creating a feedforward cycle of increasing plasma glucose levels leading to impaired insulin secretory function, further worsening hyperglycemia.

Although high glucose-induced impairment in insulin secretion is well recognized, the mechanisms causing this phenomenon are not well understood. For example, it has been proposed that chronic high-glucose-induced impairment in β-cell function can result from ‘β-cell exhaustion’ (Sako & Grill 1990, Kaiser et al. 1991, Eizirik et al. 1992, Ling et al. 1996), although this has not been a consistent finding (Davalli et al. 1991). Another possible mechanism is a reduction in insulin gene transcription factors (e.g. PDX-1 and RIPE3b1) leading to decreased β-cell insulin content (Robertson et al. 1992, Poitout et al. 1996, Moran et al. 1997, Marshak et al. 1999). However in at least one study, reduction of the transcription factor PDX-1 using a specific antisense oligodeoxynucleotide did not lead to decreased insulin levels (Kajimoto et al. 1997).

Advanced glycation end products (AGEs) accumulate in cells and tissues as a result of chronic high glucose exposure and are thought to be an important mechanism in the pathogenesis of diabetic complications (Forbes et al. 2003). It has been proposed that the in vitro accumulation of AGEs may lead to impaired β-cell function (Matsuoka et al. 1997, Tajiri et al. 1997, Kajimoto et al. 1999, Kaneto et al. 1999). Proposed AGE-related defects in insulin secretion include reduced insulin biosynthesis (Tajiri et al. 1997) as a result of diminished insulin gene promoter activity (Matsuoka et al. 1997) and reduced β-cell mass (Piercy et al. 1998, Kaneto et al. 1999).
The DBA/2 and the C57BL/KsJ mouse strain, which carries a small portion of the DBA/2 genome (Naggert et al. 1995), have a genetic predisposition to pancreatic islet failure. Islet function is grossly impaired in DBA/2 and C57BL/KsJ mice expressing the db/db gene (which results in obesity and insulin resistance as a result of a defective leptin receptor molecule) with an absence of both first and second phase insulin secretion. The hyperglycemia which develops is a consequence of decreased insulin production from a reduction in the islet β-cell population (Baetens et al. 1978, Leiter et al. 1981, Molina et al. 1984). By contrast, expression of the db/db gene on a C57BL/6 genetic background results in marked obesity, insulin resistance, with only mild hyperglycemia and marked hyperinsulinemia (Leiter et al. 1981). Furthermore, when islets from C57BL/KsJ mice are exposed to a high glucose environment by intrasplenic transplantation in syngeneic donors made hyperglycemic by treatment with streptozotocin, they show a depressed rate of cell proliferation and are eliminated within 12 days (Leiter 1987). On the other hand, C57BL/KsJ islets transplanted into normoglycemic donors are retained. Moreover, chronic incubation of DBA/2 mouse islets with glucose concentrations greater than 11·1 mM caused diminished glucose-induced insulin secretion (Pehuet-Figoni et al. 1994). These studies highlight the increased susceptibility of islets from the DBA/2 and C57BL/KsJ strains to a chronic high glucose milieu. However, a mechanism for this pancreatic islet failure has not been explored.

The aim of the present study was to investigate differences in early biochemical defects in the failure-prone DBA/2 mouse compared with C57BL/6 mice using isolated islets cultured in a high glucose environment.

Materials and methods

Materials

Collagenase P was obtained from Boehringer Mannheim (Mannheim, Germany). Culture medium RPMI 1640 with L-glutamine without sodium bicarbonate was obtained from Trace Scientific Ltd (Victoria, Australia). Aminoguanidine was obtained from Sigma–Aldrich (Australia).

Animals

Male C57BL/6 and DBA/2 mice were purchased from the Walter and Eliza Hall Institute Animal Research Facility (Kew, Victoria, Australia) and housed in the Department of Medicine Animal Research Facility under a 12 hour light/dark cycle with a standard laboratory non-purified diet containing 77% of energy as carbohydrate, 20% protein and 3% of calories as fat (Barastock Products, Pakenham, Australia) provided ad libitum unless otherwise stated. All animals were 8–10 weeks of age at the time of study and all procedures described below were approved by the Royal Melbourne Hospital Animal Research Ethics Committee.

Islet isolation and culture

Pancreatic islets were isolated by collagenase digestion as previously described (Kooptiwut et al. 2002, Zraika et al. 2002). The isolation of the islets was accomplished using a Ficoll gradient and hand picking under a stereomicroscope. Islets were cultured in RPMI 1640 containing either 11·1 mM or 40 mM glucose with 10% heat inactivated fetal calf serum, 100 µg/ml penicillin, and 100 µg/ml streptomycin at 37 °C in humidified air 5% CO₂ for 10 days, with the media being changed every second day. Aminoguanidine at a final concentration of 1 mM was added to the media of half of the islets incubated with 40 mM glucose for 10 days.

Insulin secretion assay

Islets were washed twice in Krebs Ringer Bicarbonate Buffer (KRB) (111 mM NaCl, 4·8 mM KCl, 2·3 CaCl₂, 1·2 mM MgSO₄, 1·2 mM KH₂PO₄, 25 mM NaHCO₃, pH 7·4), 10 mM Hepes, 2·8 mM glucose, 0·2% BSA fraction V (Sigma) and preincubated in the same buffer for 90 min at 37 °C in humidified air 5% CO₂. Triplicate batches of five islets were transferred to borosilicate tubes containing 1 ml of KRB supplemented with either 2·8 mM glucose, 20 mM glucose or 20 mM glucose plus 275 µM tolbutamide and incubated for 60 min at 37 °C. The medium was collected after gentle centrifugation and stored at −20 °C for measurement of insulin.

Measurement of advanced glycation end products

The AGE-associated fluorescence (Ex 370 nm, Em 440 nm) was estimated in media samples following enzymatic hydrolysis with proteinase K (10 µg/ml). Samples were then analyzed using an on-line spectrofluorometric detection flow system as previously described by our group (Forbes et al. 2002). Results were expressed in arbitrary units (AU) corrected for the protein/peptide content of each sample estimated by an on-line absorbance detector (A 280).

Islet insulin content

Islets were lysed in ice cold acid-ethanol (2% HCl in 95% ethanol) and placed at −20 °C for at least 1 h. The samples were thawed and sonicated on ice for about
20 min to complete the lysis. The supernatants were collected after gentle centrifugation (900 g for 5 min at 4 °C) and kept at -70 °C until measurement of insulin content by radioimmunoassay.

### Real-time quantitative RT-PCR

Gene expression of mouse pro-insulin II in isolated pancreatic islets was determined using real-time quantitative RT-PCR performed using the TaqMan system (ABI Prism 7700, Perkin-Elmer Corp, PE Biosystems, Foster City, CA, USA), as previously described (Tikellis et al. 2003, 2004). Total RNA was extracted from freshly isolated pancreatic islets following homogenisation using the Ultra-Turrax (Janke & Kunkel IKA, Labortechnik, Germany) in TRIZOL (Life Technologies Inc, Gaithersburg, MD, USA). cDNA was then synthesized with a reverse transcriptase reaction carried out using standard techniques (Superscript First Strand Synthesis System for RT-PCR, Life Technologies Inc) with random hexamers, dNTPs and total RNA. To assess genomic DNA contamination, controls without reverse transcriptase were included. The oligonucleotides and probe for mouse pro-insulin II were designed using the software program, ‘Primer Express’ (PE Applied Biosystems, Foster City, CA, USA) and are 3’ oligonucleotide (5’-TCAAGCAGGACCTTTGTG GTT), 5’ oligonucleotide (5’-GGGACATGGGTGTGT AGAAGAA) and probe (FAM5’-CCCACACACCAG GTAG-MGB).

The RT-PCR multiplex reaction took place with 500 nmol/l of forward and reverse primer and 50 nmol/l of FAM/MGB probe and VIC/TAMRA 18S ribosomal probe, in Taqman universal PCR master mix (PE Biosystems, Foster City, CA, USA). Amplification of 18S was used to correct for loading. Each sample was run and analyzed in triplicate.

### Measurement of glucose phosphorylating activity

Approximately 300 islets were washed with 2.8 mM KRB twice and incubated for another 90 min. Islets were homogenized in ice-cold buffer containing 20 mM K$_2$HPO$_4$, 1 mM EDTA, 5 mM dithiothreitol and 110 mM KCl. The islet homogenate was then centrifuged at 12 000 g for 10 min. The supernatant was collected after gentle centrifugation (900 g for 5 min at 4 °C) and the pellet resuspended in Hanks’ Balanced Salt Solution (HBSS). Cells were then incubated with trypsin/EDTA for 15–20 min at 37 °C. The cell suspension was then centrifuged at 900 g for 10 min at 4 °C and the pellet resuspended in Hanks’ Balanced Salt Solution (HBSS). Cells were then incubated with trypsin blue (final concentration, 0.2 mg/ml) for 3–5 min and observed under a microscope. Viable (unstained) and non-viable (stained) cells were counted with a hemocytometer and the viable cell ratio calculated.

### Glucokinase, hexokinase and GLUT2 Western blot analysis

Western blot analyses were performed as previously described (Kooptiwut et al. 2002) to quantify glucokinase, hexokinase and GLUT2 protein levels. Following incubation, approximately 400–500 islets were sonicated for 20 min at 4 °C in a lysis buffer containing 5% SDS, 80 mM Tris /HCl, pH 6-8, 5 mM EDTA, 1 mM phenylmethylsulfonylfluoride, 10 µg DNase I, and 0-2 mM N-ethylmaleimide. The lysate was retrieved after centrifugation at 12 000 g for 10 min at 4 °C. Protein content was measured by the Bio-Rad protein assay kit (Bio-Rad, Hercules, CA, USA). Samples containing 20 µg of protein were resolved by electrophoresis through a 10% (for glucokinase and GLUT2) or 7.5% (for hexokinase) polyacrylamide gel. Following transfer to PVDF membrane glucokinase was immunodetected using a specific anti-glucokinase antibody (cat # sc-7908, Santa Cruz Biotech. Inc, Santa Cruz, CA, USA) at a 1:500 dilution followed by incubation with swine anti-rabbit IgG at 1:2500 dilution. Hexokinase was immunodetected using a specific anti-hexokinase antibody (cat # sc-6517, Santa Cruz Biotech. Inc) at a 1:500 dilution followed by incubation with swine anti-goat IgG at 1:2500 dilution. GLUT2 was immunodetected using a specific anti-GLUT2 antibody (cat # sc-9117, Santa Cruz Biotech. Inc) at a 1:2000 dilution followed by incubation with swine anti-rabbit IgG at 1:2500 dilution. Protein bands were visualized by enhanced chemiluminescence (Renaissance, NEN Life Science Products Inc, Boston MA, USA) and quantified using scanning densitometry.
Statistical Analysis

Insulin secretion results were corrected for and expressed as the percent of total islet insulin content. Data is presented as mean ± S.E.M. for the number indicated. Statistical analysis was performed using the Mann–Whitney U test and the Wilcoxon paired test. A *P* < 0.05 was considered significant.

Results

Islet culture in 11·1 mM or 40 mM glucose for 10 days

Isolated DBA/2 and C57BL/6 mouse islets were cultured in 11·1 mM glucose for 10 days, insulin release was assessed at basal (2·8 mM) and stimulating (20 mM) glucose concentrations. Fig. 1A shows that insulin release was stimulated with 20 mM glucose from both DBA/2 and C57BL/6 mouse islets. As we have previously shown (Kooptiwut et al. 2002) insulin release was increased from DBA/2 compared with C57BL/6 islets at both 2·8 mM and 20 mM glucose.

Incubation of the islets with 40 mM glucose for 10 days increased basal insulin release in both DBA/2 (35·2 ± 5·8 vs 1·2 ± 0·2% content, *P* < 0·05) and C57BL/6 (17·9 ± 6·0 vs 0·3 ± 0·1% content, *P* < 0·05) mice but the increase was more marked in DBA/2 compared with C57BL/6 islets (*P* < 0·05). When stimulated with 20 mM glucose insulin secretion was significantly increased from C57BL/6 islets while there was no change from DBA/2 islets when compared with 2·8 mM glucose condition (Fig. 1A). However, when challenged with 20 mM glucose +275 µM tolbutamide, there was a significant increase in insulin release from DBA/2 islets (*P* < 0·05). This suggests a functional defect in DBA/2 islets when chronically incubated with 40 mM glucose.

To determine the effects of advanced glycation end products on secretory function, aminoguanidine was added to DBA/2 and C57BL/6 islets cultured for 10 days in 40 mM glucose. Incubation of islets in the presence of 1 mM aminoguanidine significantly reduced basal insulin secretion in DBA/2 (35·2 ± 5·8 vs 5·9 ± 1·0% content, *P* < 0·05) and C57BL/6 (17·9 ± 6·0 vs 2·5 ± 0·5% content, *P* < 0·05) mouse islets but the increase was more marked in DBA/2 compared with C57BL/6 islets (*P* < 0·05). When stimulated with 20 mM glucose insulin secretion was significantly increased from C57BL/6 islets while there was no change from DBA/2 islets when compared with 2·8 mM glucose condition (Fig. 1A). However, when challenged with 20 mM glucose +275 µM tolbutamide, there was a significant increase in insulin release from DBA/2 islets (*P* < 0·05). This suggests a functional defect in DBA/2 islets when chronically incubated with 40 mM glucose.

To determine the effects of advanced glycation end products on secretory function, aminoguanidine was added to DBA/2 and C57BL/6 islets cultured for 10 days in 40 mM glucose. Incubation of islets in the presence of 1 mM aminoguanidine significantly reduced basal insulin secretion in DBA/2 (35·2 ± 5·8 vs 5·9 ± 1·0% content, *P* < 0·05) and C57BL/6 (17·9 ± 6·0 vs 2·5 ± 0·5% content, *P* < 0·05) mouse islets but the increase was more marked in DBA/2 compared with C57BL/6 islets (*P* < 0·05). When stimulated with 20 mM glucose insulin secretion was significantly increased from C57BL/6 islets while there was no change from DBA/2 islets when compared with 2·8 mM glucose condition (Fig. 1A). However, when challenged with 20 mM glucose +275 µM tolbutamide, there was a significant increase in insulin release from DBA/2 islets (*P* < 0·05). This suggests a functional defect in DBA/2 islets when chronically incubated with 40 mM glucose.

Figure 1 (A) Glucose-mediated insulin secretion in islets incubated with 11·1 mM glucose or 40 mM glucose in the absence or presence of 1 mM aminoguanidine (AG) for 10 days. Islets from 8–10 week-old DBA/2 and C57BL/6 mice were isolated as described in the Materials and methods section and batches of five islets preincubated in KREBS buffer containing 2·8 mM glucose for 90 minutes. Insulin secretion was assessed at 2·8 mM glucose, 20 mM glucose or 20 mM glucose +275 µM tolbutamide over a 60 min period. (B) Insulin secretion expressed as fold increase of the result obtained with 2·8 mM glucose. Results are presented as means±S.E.M. (*n* = 6). *P* < 0·05 compared with C57BL/6 mouse islets, †*P* < 0·05 compared with islets incubated with 1 mM aminoguanidine, ‡*P* < 0·05 compared with islets incubated in 11·1 mM glucose for 10 days, &*P* < 0·05 compared with islets stimulated with 2·8 mM glucose for 60 minutes, †*P* < 0·05 compared with islets incubated with 11·1 mM glucose for 10 days.
C57BL/6 islets (Fig. 2). Aminoguanidine resulted in a reduction in AGE in both strains of mice.

**Islet insulin content and mRNA**

Insulin content and mRNA levels in islets cultured with 11.1 mM or 40 mM glucose for 10 days is shown in Fig. 3. There was a marked decrease in islet insulin content following 40 mM glucose compared with 11.1 mM glucose culture in both strains of mice, with no difference in insulin content between DBA/2 and C57BL/6 islets (Fig. 3A). Treatment with aminoguanidine resulted in increased insulin content in islets from both strains of mice incubated with 40 mM glucose (Fig. 3A). However, DBA/2 mouse islets contained significantly less insulin following 40 mM glucose plus aminoguanidine treatment compared with similarly treated C57BL/6 mouse islets.

In contrast insulin mRNA was significantly increased in both DBA/2 and C57BL/6 islets following incubation in 40 mM glucose for 10 days (Fig. 3B). Aminoguanidine had no effect on insulin mRNA in either strain compared with 40 mM glucose incubation for 10 days. There was a trend (P=0.1) for insulin mRNA to be higher in DBA/2 compared with C57BL/6 islets incubated with 11.1 mM glucose for 10 days (Fig. 3B).

**Cell viability**

Cell viability was determined under the culture conditions described above and the data shown in Fig. 4. Chronic high glucose culture resulted in decreased cell viability in both strains, being statistically significant at 6, 8 and 10 days for C57BL/6 (Fig. 4A) and at 8 and 10 days for DBA/2 (Fig. 4B) mouse islets. At 10 days, cell viability was the same between C57BL/6 and DBA/2 mice (72.6 ± 1.0% vs 74.0 ± 1.8%, P=0.52). Aminoguanidine treatment completely reversed the decrease in cell viability caused by high glucose in both strains of mice (Figs 4A and B).

**Islet glucokinase, hexokinase and GLUT2 Levels**

A possible mechanism was investigated for the changes in insulin secretion in DBA/2 mouse islets incubated with 40 mM glucose in the presence of comparable insulin content and cell viability between the two strains of mice. To determine whether the altered insulin secretion in DBA/2 islets following chronic high glucose was the result of impaired glucose sensing, the protein levels of glucokinase, hexokinase and GLUT2 were measured and the results shown in Fig. 5. Western blotting on freshly isolated islets showed that glucokinase...
levels were comparable between the two strains of mice (18.9 ± 0.6 vs 20.0 ± 1.3 arbitrary units C57BL/6 vs DBA/2, n=3, P=0.5). Glucokinase protein levels were also similar between DBA/2 and C57BL/6 islets following 11.1 mM glucose culture for 10 days. Culture with 40 mM glucose for 10 days resulted in reduced glucokinase in DBA/2 but not C57BL/6 islets. Furthermore, glucokinase protein levels were also 50% lower in DBA/2 mouse islets than that detected in C57BL/6 mouse islets (Fig. 5). In addition glucokinase activity was also decreased in DBA/2 compared with C57BL/6 islets following high glucose culture (2.6 ± 0.5 vs 3.8 ± 0.5 nmol/min/mg protein, n=6, P=0.05). Aminoguanidine treatment resulted in significantly increased glucokinase protein levels in DBA/2 mouse islets incubated with 40 mM glucose for 10 days (Fig. 5).

To determine the effect of chronic high glucose on the protein levels of other components of the glucose sensing system, GLUT2 and hexokinase levels were measured and the results shown in Fig. 6. There was no difference in GLUT2 protein levels between the two strains of mice (Fig. 6A). The lack of change in hexokinase activity (3.1 ± 0.3 vs 3.2 ± 0.9 nmol/min/mg protein, n=6, P=0.4) was also reflected in no change in hexokinase protein levels (Fig. 6B).

**Discussion**

Glucokinase is the β-cell glucose-sensor for insulin secretion (Steiner & James 1992, Matschinsky 1996, ...
Deletion of one allele of β-cell glucokinase by homologous recombination in mice resulted in reduced glucose-mediated insulin release (Terauchi et al. 1995, Andrikopoulos et al. 2000). Interestingly while stimulated insulin levels were lower in the heterozygous knockout mice, basal insulin levels were not different to wildtype and were trending towards being higher (Terauchi et al. 1995, Andrikopoulos et al. 2000). In the present study we showed that chronic high glucose incubation caused a 50% decrease in glucokinase protein levels and this was associated with a reduction in glucose-stimulated insulin release from DBA/2 islets. This is in contrast to a previous study which showed an increase in glucokinase activity levels following high glucose culture (Liang et al. 1994). The reason for the discrepancy could be due to a difference in strain backgrounds (a hybrid background vs DBA/2 in our study) and the length of time and concentration of glucose (30 mM for 4 days vs 40 mM glucose for 10 days in our study). While chronic 40 mM glucose incubation resulted in increased basal insulin secretion, this occurred in both strains of mice. Furthermore tolbutamide was able to elicit a significant increase in insulin release from DBA/2 islets incubated chronically with 40 mM glucose. Thus while the increase in basal insulin secretion may have been a contributory factor, we believe that the reduction in islet glucokinase was the main cause of the reduction in function of DBA/2 islets. Increases in basal insulin secretion following high glucose culture have previously been shown in rat islets and purified β-cells (Purrello et al. 1989, Ling et al. 1996, Tajiri et al. 1997). Furthermore, we showed that aminoguanidine, an inhibitor of the glycation process, reduced basal insulin secretion in both DBA/2 and C57BL/6 islets following high glucose culture, but was associated with significant increases in glucokinase levels only in the DBA/2 mouse. This further supports the notion that the effect of high glucose to reduce glucose-mediated insulin secretion from the DBA/2 islet is associated with reduced glucokinase levels.

Formation of advanced glycation end products has been shown to be detrimental to islet function, an effect improved by aminoguanidine (Tajiri et al. 1997). This is corroborated by a study in the immortal β-cell line HIT-T15 in which induction of glycation suppressed the activity of the glucokinase promoter resulting in reduced mRNA and protein levels (Kajimoto et al. 1999). Furthermore it was shown that the inhibition of glucokinase gene expression was prevented by treatment
with N-acetyl-cysteine or aminoguanidine providing further evidence that increased glycation was involved (Kajimoto et al. 1999). While it has been suggested that aminoguanidine may act by inhibiting nitric oxide synthase, evidence suggests that in pancreatic islets the main mechanism of action is via reduction of AGE (Tajiri et al. 1997). This study demonstrated that N^6^-Methyl-L-arginine, a nitric oxide synthase inhibitor, failed to reproduce the beneficial effects of aminoguanidine in rat islets. It has also been shown that the effects of aminoguanidine on insulin secretion are not via inhibition of glucose oxidation (Eizirik et al. 1994). One may also argue that aminoguanidine itself is directly increasing glucokinase levels and thus its effect is independent of glycation inhibition. However, we did not see a similar increase in glucokinase protein levels in control C57BL/6 islets treated with aminoguanidine. It is of interest that the increase in AGE with high glucose culture was similar in DBA/2 and C57BL/6 islets, yet only the former displayed a defect in insulin secretion, associated with reduced glucokinase levels. Furthermore the fact that these phenotypic differences between the two strains were present in vitro 10 days after removal from the in vivo situation indicates that they are due to genetic variations. This suggests that DBA/2 mice are not able to cope with oxidative stress as well as C57BL/6 mice and this may be due to the inherent susceptibility of DBA/2 islets to develop diabetes when exposed to a permissive environment (Leiter et al. 1981, Leiter 1987, Pehuet-Figoni et al. 1994).

Other explanations have been proposed for high glucose induced impairments in insulin release. Chronic high glucose incubation has been shown to cause excessive insulin secretion depleting intracellular stores (Sako & Grill 1990, Kaiser et al. 1991, Eizirik et al. 1992, Ling et al. 1996, Bjorklund et al. 2000), this effect being prevented by agents, such as diazoxide (Sako & Grill 1990, Bjorklund et al. 2000), that inhibit insulin release. It has also been suggested that chronic high glucose resulted in reduced insulin biosynthesis as a result of decreased expression of the insulin gene transcription factors PDX-1 and RIPE-3b1 (Robertson et al. 1992, Poitout et al. 1996, Moran et al. 1997, Marshak et al. 1999). Consequently increased D-ribose induced glycation has been shown to cause a decrease in insulin gene promoter activity, which was prevented by aminoguanidine (Matsuoka et al. 1997). Moreover, aminoguanidine has been shown to cause an increase in proinsulin biosynthesis while decreasing AGE-related fluorescence in rat islets chronically incubated with 38 mM glucose (Tajiri et al. 1997). Lastly, aminoguanidine and other antioxidants have been shown to increase β-cell mass in diabetic C57BL/KsJ-db/db mice (Kaneto et al. 1999, Piercy et al. 1998).

In our study we found that incubation with 40 mM glucose caused reduced insulin content and cell viability in both DBA/2 and C57BL/6 islets. Aminoguanidine treatment caused a significant increase in islet insulin content and cell viability in cells incubated with 40 mM glucose in both DBA/2 and C57BL/6 islets. The failure to find a difference in cell survival between the DBA/2 and C57BL/6 islets was surprising given the existing data showing a marked difference in survival of these islets when exposed in vivo to hyperglycemia (Baetens et al. 1978, Leiter et al. 1981, Molina et al. 1984). The difference could be due to the duration of the exposure to hyperglycemia or to the presence of other factors contributing to cell death in the DBA/2 mice that are present in vivo but not in vitro. It is likely that a separate mechanism operates in DBA/2 mice exposed to hyperglycemia for longer. However it appears that aminoguanidine can also block this mechanism since it has been shown that this agent prevents β-cell death when administered in vivo to C57BL/KsJ-db/db mice (Kaneto et al. 1999, Piercy et al. 1998).

Interestingly we found that islet insulin mRNA was in fact increased following 40 mM glucose culture for 10 days and that aminoguanidine had no further effect in both strains of mice. Thus, the increase in insulin content that we observe in both the DBA/2 and C57BL/6 islets following aminoguanidine treatment is most probably due to a decrease in chronic secretion or an increase in cell viability or more likely a combination of both of these processes. However, since there was no difference in islet insulin content, insulin mRNA and cell viability between the two strains of mice regardless of culture condition, these cannot explain the changes in insulin release in the DBA/2 mouse following 40 mM glucose exposure for 10 days. This provides further support for our finding that reduction of glucokinase levels may be responsible for the impairment of secretory function following chronic high glucose exposure of DBA/2 but not C57BL/6 islets.

In conclusion, we show that islets from susceptible DBA/2 mice display increased basal insulin secretion and decreased glucose-stimulated secretory function when chronically incubated in high glucose associated with a decrease in glucokinase but not hexokinase levels. Furthermore, treatment with aminoguanidine, which is an inhibitor of the glycation process, was able to reduce basal insulin secretion, increase glucokinase protein levels and prevent this reduction in function in DBA/2 islets. Thus, in our study we demonstrate that hyperglycemia has multiple effects on islets, such as cell viability, reduced insulin content, increased insulin mRNA, which do not vary between mouse strains, yet these strains differ in their susceptibility to β-cell failure. In contrast, islets from a mouse with increased β-cell failure susceptibility have abnormal regulation of glucokinase. How this occurs, or if this is related to subsequent β-cell failure is not clear and warrants further study.

Journal of Molecular Endocrinology (2005) 35, 39–48

www.endocrinology-journals.org

Downloaded from Bioscientifica.com at 10/16/2018 02:40:46AM
via free access
Acknowledgements

We would like to thank Sue Franchescini, Marisa Fielding, Naomi Kujala and Paul Brazzoduro for excellent technical assistance. This study was supported by grants from the Diabetes Australia Research Trust (to SA, MD and JP) and the National Health and Medical Research Council of Australia (# 114163 to SA and JP). The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

References


decreases binding of the RIPE3b1 insulin gene transcription activator. *Journal of Clinical Investigation* 97:1041–1046.


Received in final form 19 April 2005
Accepted 21 April 2005
Made available online as an Accepted Preprint 13 May 2005